OncologyTube.com is the first and only free video sharing website dedicated to helping oncology professionals spread knowledge about cancer research through video, audio and other multimedia.
    • OncologyTube

      Site: OncologyTube

    • Products & Pricing
      • Banner Advertising Plans
      • Pre-Roll Advertising
      • Create a Video Release (VR)
      • Boost Earned Media Only $60
      • Create A Deep Dive Conversation
      • Portuguese
      • Spanish
      • Italian
      • Greek (Greece)
      • Sinhala
      • Polish
      • Arabic (Saudi Arabia)
      • Swedish (Sweden)
      • Portuguese (Brazil)
      • Hindi (India)
      • English (Australia)
      • Hebrew (Israel)
      • Czech
      • Chinese
      • Turkish
      • Japanese (Japan)
      • Dutch
      • French
      • German
      • Chinese (Traditional Han, Taiwan)
      • Korean (South Korea)
      • Thai
      • Spanish (Chile)
      • English (United States)
      • Russian
      • Danish (Denmark)
  • Home
  • Trending

  • Login

  • Quick Links
  • Schedule A Remote Interview!
  • Check Out Our Blog
  • Buy Advertising Banners
  • Buy Pre-Roll Advertisements
  • Boost Your Earned Media starting at Just $60
  • Create A Deep Dive Conversation
  • Advertising Specifications
  • Our Editorial Process

  • Audio and Video
  • Videos
  • Audio

  • Channels
  • Browse Channels

  • Categories
  • Acute Lymphoblastic Leukemia 5574
  • Acute Myelogenous Leukemia 218
  • Bladder 95
  • Bone Metastases 4
  • Brain 77
  • Breast 433
  • Business Management 5
  • Cervical 16
  • Chronic Lymphocytic Leukemia 200
  • Chronic Myelogenous Leukemia 49
  • Colorectal 161
  • COVID-19 42
  • Gastrointestinal 175
  • General 334
  • Head and Neck 95
  • Help 3
  • Hematologic Malignancies 185
  • Hodgkin Lymphoma 31
  • Imaging 2
  • Immunotherapy 178
  • Kidney 389
  • Liver 38
  • Lung 72
  • Lymphoma 216
  • Melanoma and Skin 100
  • Multiple Myeloma 507
  • Myeloproliferative Disease 25
  • News 149
  • Non-Hodgkin Lymphoma 78
  • Non-Small Cell Lung Cancer 505
  • Other 512
  • Ovarian 64
  • Pancreatic 100
  • Patient Resources 51
  • Pediatric 6
  • Prostate 285
  • Sickle Cell 22
  • Small Cell Lung Cancer 78
  • Soft Tissue Sarcoma 12
  • Supportive Care 47
  • Testicular 3
  • Urology 16
  • Uterine 9

  • Install
  • Play a Link
  • About
  • Contact
  • Acute Lymphoblastic Leukemia 5574
  • Acute Myelogenous Leukemia 218
  • Bladder 95
  • Bone Metastases 4
  • Brain 77
  • Breast 433
  • Business Management 5
  • Cervical 16
  • Chronic Lymphocytic Leukemia 200
  • Chronic Myelogenous Leukemia 49
  • Colorectal 161
  • COVID-19 42
  • Gastrointestinal 175
  • General 334
  • Head and Neck 95
  • Help 3
  • Hematologic Malignancies 185
  • Hodgkin Lymphoma 31
  • Imaging 2
  • Immunotherapy 178
  • Kidney 389
  • Liver 38
  • Lung 72
  • Lymphoma 216
  • Melanoma and Skin 100
  • Multiple Myeloma 507
  • Myeloproliferative Disease 25
  • News 149
  • Non-Hodgkin Lymphoma 78
  • Non-Small Cell Lung Cancer 505
  • Other 512
  • Ovarian 64
  • Pancreatic 100
  • Patient Resources 51
  • Pediatric 6
  • Prostate 285
  • Sickle Cell 22
  • Small Cell Lung Cancer 78
  • Soft Tissue Sarcoma 12
  • Supportive Care 47
  • Testicular 3
  • Urology 16
  • Uterine 9
Podcast - Miranda Gogishvili, MD #HighTechnologyMedicalCenter #UniversityClinic #ESMO21 #NonSmallCellLungCancer #NSCLC #Cancer #Research Abstract - LBA51 - EMPOWER-Lung 3 Study
0:06:04

Podcast - Miranda Gogishvili, MD #HighTechnologyMedicalCe...

Miranda Gogishvili, MD High Technology Medical Center, University Clinic speaks about ESMO 2021 Abstract - LBA51 - EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC).

Link to Abstract:
https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/empower-lung-3-cemiplimab-in-combination-with-platinum-doublet-chemotherapy-for-first-line-1l-treatment-of-advanced-non-small-cell-lung-cancer

Abstract LBA51

Background:

EMPOWER-Lung 3 is a two-part, randomized Phase 3 trial of 1L therapy in patients with advanced (Stage III/IV) squamous (SQ) or non-squamous (NSQ) NSCLC who do not have actionable mutations (NCT03409614). The study's double-blind Part 2 enrolled patients regardless of their PD-L1 levels and compared the clinical activity and safety of cemiplimab, an anti-PD-1, plus (+) platinum-based chemotherapy to (vs) placebo (PBO)+chemo.

Methods:

Pts were randomly randomized (2:1; stratified by histology and PD-L1 expression) to receive cemiplimab 350 mg Q3W or PBO Q3W for 108 weeks (or until progression), plus up to four chemo cycles (followed by mandatory pemetrexed maintenance for NSQ pts assigned to a pemetrexed-containing regimen). Overall survival was the primary outcome (OS). Per blinded independent central review, key secondary objectives include progression-free survival (PFS) and objective response rate (ORR). Part 2 of the pre-specified 2nd interim analysis is shown here. The deadline for submitting data was June 14, 2021.

Results:

Overall, 466 patients were screened and assigned to one of two groups: cemiplimab+chemo (n=312) or PBO+chemo (n=154). The median (range) age of the participants was 63.0 (25-84) years, with 57.1 percent having NSQ NSCLC and 85.2 percent having Stage IV illness. With cemiplimab+chemo, the median OS was 21.9 months compared to 13.0 months with PBO+chemo (HR, 0.71; P=0.014). Compared to PBO+chemo, cemiplimab+chemo had a better median PFS (8.2 vs 5.0 months; HR, 0.56), a greater ORR (43.3 vs 22.7 percent), and a longer median duration of response (DOR) (15.6 vs 7.3 months) (Table). Grade 3 adverse events occurred 43.6 percent of the time in the cemiplimab+chemo arm and 31.4 percent of the time in the PBO+chemo arm.

Conclusions:

In patients with advanced NSCLC, 1L cemiplimab with chemo improved OS, PFS, ORR, and DOR compared to chemo alone, with a safety profile similar to cemiplimab monotherapy and platinum-based chemo.

Clinical trial identification
NCT03409614.

12 Views
10 months ago
ESMO
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Non-Small Cell Lung Cancer

Lung Cancer Video Library - Immunotherapy for Patients with Driver Mutation
0:05:59
Lung Cancer Video Library - Immunotherapy for Patients wi...
0 Views
2 weeks ago
Cancer
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Melanoma & CD8 Killer T Cells
0:07:25
Melanoma & CD8 Killer T Cells
180 Views
1 month ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Audio: Targeting K-RAS in Lung Cancer is a Goliath Task (But We Have Some Answers) - Jia Luo, MD @Jia_Luo @DanaFarber @harvardmed #ASCO22 #OncoTwitter
0:05:25
Audio: Targeting K-RAS in Lung Cancer is a Goliath Task (...
7 Views
1 month ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Video: Targeting K-RAS in Lung Cancer is a Goliath Task (But We Have Some Answers) - Jia Luo, MD @Jia_Luo @DanaFarber @harvardmed #ASCO22 #OncoTwitter
0:05:25
Video: Targeting K-RAS in Lung Cancer is a Goliath Task (...
13 Views
1 month ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Article: Transcript: Targeting K-RAS in Lung Cancer is a Goliath Task (But We Have Some Answers) - Jia Luo, MD @Jia_Luo @DanaFarber @harvardmed #ASCO22 #OncoTwitter
Article: Transcript: Targeting K-RAS in Lung Cancer is a ...
26 Views
1 month ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast Charles Ricordel, MD @C_Ricordel @CHURennes @UnivRennes1 #ASCO22 #OncoTwitter @oncoalert Phase 1/2 CEACAM5 Study
0:05:15
Podcast Charles Ricordel, MD @C_Ricordel @CHURennes @Univ...
7 Views
1 month ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Charles Ricordel, MD @C_Ricordel @CHURennes @UnivRennes1 #ASCO22 #OncoTwitter @oncoalert Phase 1/2 CEACAM5 Study
0:05:15
Charles Ricordel, MD @C_Ricordel @CHURennes @UnivRennes1 ...
104 Views
1 month ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast Trevor M. Feinstein, MD #PiedmontCancerInstitute #ASCO22 #OncoTwitter @oncoalert DUBLIN-3 Phase III Study
0:05:53
Podcast Trevor M. Feinstein, MD #PiedmontCancerInstitute ...
9 Views
2 months ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Plinabulin Improved OS lower Toxicity in NSCLC EGFR
0:05:53
Plinabulin Improved OS lower Toxicity in NSCLC EGFR
106 Views
2 months ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast Mary O'Brien, MD @drMaryOBr @royalmarsdenNHS #ASCO22 #OncoTwitter Phase III PEARLS/KEYNOTE-091 Discussion
0:11:55
Podcast Mary O'Brien, MD @drMaryOBr @royalmarsdenNHS #ASC...
5 Views
2 months ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Mary O'Brien, MD @drMaryOBr @royalmarsdenNHS #ASCO22 #OncoTwitter Phase III PEARLS/KEYNOTE-091 Discussion
0:11:55
Mary O'Brien, MD @drMaryOBr @royalmarsdenNHS #ASCO22 #Onc...
83 Views
2 months ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Podcast Roy S. Herbst, MD @DrRoyHerbstYale @YaleCancer #ASCO22 Phase II S1800A Trial
0:02:29
Podcast Roy S. Herbst, MD @DrRoyHerbstYale @YaleCancer #A...
8 Views
2 months ago
Annual Meeting
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Copyright 2022 Medicus Networks, Inc. 45121 Morgan Heights Rd. Temecula, CA 92592